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INTRODUCTION 
Oral delivery is the preferred administration route for drugs. 
Sometimes it can be necessary to employ advanced drug 
delivery systems to achieve targeted and/or sustained 
delivery in the gastro-intestinal (GI) tract after oral 
administration. Micro fabricated drug delivery devices have 
been proposed as an advanced drug delivery systems being 
able to increase the oral bioavailability of drugs [Chirra et 
al., 2012]. Of these micro devices, microcontainers are 
suggested as especially promising [Chirra et al., 2014]. 
Primarily, this is due to the fact that the size and shape of 
the microcontainers can be controlled very precisely and 
therefore, polydispersity as seen example for micro- and 
nanoparticles is avoided [Randall et al., 2007]. 
Microcontainers are polymeric, cylindrical devices in the 
micrometer size range (Figure 1). A major advantage is that 
these devices allow for unidirectional release, as only one 
side of the microcontainers is open compared to 
microparticles where release can occur over the whole area 
of the particle [Nielsen et al., 2012], [Nielsen et al., 2014].   
 
  
Figure 1: SEM image of a microcontainer  
 
The purpose of these studies was to fabricate 
microcontainers in either SU-8 or biodegradable poly-L-
lactic acid (PLLA), and fill the microcontainers with poorly 
soluble drugs or vaccine particulates. Furthermore, the 
application of the microcontainers as an oral drug delivery 
system was investigated in terms of release, in situ 
intestinal perfusion and oral bioavailability. 
 
 
 
EXPERIMENTAL  
SU-8 microcontainers were fabricated using lithography, 
whereas PLLA microcontainers were prepared by hot 
embossing. In terms of drug filling, the SU-8 
microcontainers were filled with polyvinylpyrrolidone 
(PVP) by inkjet printing followed by supercritical CO2 
impregnation of ketoprofen into the PVP matrix. As an 
alternative filling method, the powder of amorphous sodium 
salt of furosemide (ASSF) or cubosomes with ovalbumin 
were filled into the SU-8 microcontainers. The PLLA 
microcontainers were filled with drug formulation by 
embossing the microcontainers into a polycaprolactone 
(PCL) and furosemide (4:1 w/w) layer.  
For the ASSF-filled microcontainers, an enteric-resistant lid 
of Eudragit L100 was spray coated onto the cavity of the 
microcontainers. Release of ASSF from the coated 
microcontainers was investigated using a µ-Diss profiler in 
simulated intestinal medium at pH 6.5. Closed loop in situ 
intestinal perfusions were performed in rats of the Eudragit-
coated ASSF-filled microcontainers and compared to a 
furosemide solution. The microcontainers were dosed to the 
small intestine, and at the end of the study, the small 
intestine was harvested from the rat and imaged under a 
light microscope. For the in vivo studies, the rats were 
dosed orally with capsules containing ASSF-filled 
microcontainers coated with Eudragit L100. As control, 
capsules were filled with the powder of ASSF and the 
capsules were coated with Eudragit L100. 
 
RESULTS 
The SU-8 microcontainers had an inner diameter of 220 µm 
and a cavity depth of 270 µm (Figure 1), and for the PLLA 
microcontainers the inner diameter was found to be 240 µm 
and with a cavity depth of 65 µm (Figure 2).  
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Figure 2: SEM image of a PLLA microcontainer   
 
The microcontainers were successfully filled with either 
PVP:ketoprofen, PCL:furosemide, cubosomes or ASSF 
(Figure 3A), and the ASSF-filled microcontainers were 
coated with a lid of Eudragit L100 (Figure 3B).  
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Figure 3: A) SEM image of an ASSF-filled microcontainer B) 
followed by a coating of Eudragit L100.   
 
A fast release of ASSF from the microcontainers was 
observed and the Eudragit coating was shown not to be a 
hindrance for rapid release at intestinal conditions. For the 
intestinal perfusion studies, the absorption rate constant of 
ASSF was 1.5 fold higher, when ASSF was confined in the 
microcontainers compared to a furosemide solution. 
Micrographs of the small intestine after the perfusion 
studies showed that the microcontainers interacted with the 
mucus in the small intestine, and the microcontainers were 
engulfed by the intestinal mucus (Figure 4). This was also 
observed for empty microcontainers without drug and 
coating (Figure 4C) 
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Figure 4: Images of the microcontainers following intestinal 
perfusion studies. A) and B): Microcontainers filled with 
ASSF and coated with Eudragit L100. C) Empty 
microcontainer 
 
The oral bioavailability study showed that the relative oral 
bioavailability of ASSF in microcontainers was 220±43% 
when compared to drug-filled capsules coated with 
Eudragit (Figure 5).   
 
Figure 5: Plasma concentrations of microcontainers filled with 
ASSF coated with Eudragit L100 and filled into capsules and 
ASSF dosed in capsules with Eudragit coating after oral 
dosing to rats.   
 
CONCLUSION 
Both SU-8 and biodegradable PLLA microcontainers were 
successfully fabricated and loaded with drug/formulation. A 
fast release of ASSF was facilitated from the SU-8 
microcontainers. Furthermore, the microcontainers were 
found to interact with the intestinal mucus resulting in a 
higher oral bioavailability when compared to non-confined 
ASSF. The fabricated microcontainers therefore show 
considerable future potential as oral drug delivery systems. 
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